Drugs / corticorelin hormone
corticorelin hormone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04902235 | Jul 2021 → Apr 2023 | central diabetes insipidus, hypothalamic disorder, panhypopituitarism, psychiatric disorder | Sant Pau Research Institute | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | corticorelin hormone | “In animal models, corticorelin hormone (CRH) has shown to increase OT release.” NCT04902235 ↗ |
| Known as | Corticotropin-releasing hormone | “Corticotropin-releasing hormone (CRH) is a candidate for such a test as it increases oxytocin secretion in animal models.” PMID 39824923 ↗ Jan 2025 |
| Known as | CRH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04902235 ↗ |
| Route | Intravenous | “CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds” NCT04902235 ↗ |